A Novel PTPN2 Isoform Differentially Regulates Immune Response
European Journal of Immunology · 2026-05 · 56 (5)
DOI: 10.1002/eji.70207 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 19.05.2026. Verfasst von Xiaoguang Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Discovery Research, AbbVie, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 2, Crohn Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Inc., AbbVie.
Abstract (Originalsprache)
Genome‐wide association studies implicate the PTPN2 gene locus (18p11.21) in risk for several autoimmune diseases, including inflammatory bowel disease. Through genetic fine mapping, we identified the single‐nucleotide polymorphism rs80262450 in the PTPN2 gene as the putative causal variant. Analysis of GTEx tissue samples and genetically engineered myeloid cell lines carrying risk and nonrisk alleles of rs80262450 demonstrated increased expression of the PTPN2 splice isoform 4 (PTPN2.4), suggesting that the rs80262450 enhances disease susceptibility by favoring production of PTPN2.4. Furthermore, we found that PTPN2.4 contains a nuclear export sequence (NES) that leads to its retention in the cytoplasm. Differential localization of PTPN2.4 isoform results in a distinct protein binding profile revealed by mass‐spectrometry analysis, and its overexpression increased TNF‐α. PTPN2.4 knockdown reduced pro‐inflammatory cytokines in human macrophages. Mutations within the NES motif abolished the unique localization and function of PTPN2.4. Lastly, increased expression of PTPN2.4 was found in Crohn's disease tissues, demonstrating its involvement in the disease. Together, we identified the pathogenic isoform PTPN2.4 as a novel driver of intestinal inflammation and a potential target to attenuate inflammation in IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology Discovery Research, AbbVie, Inc., Cambridge, Massachusetts, USA.
- Genomics Research Center, AbbVie, Inc., North Chicago, Illinois, USA.
- Small Molecule Therapeutics & Platform Technologies, AbbVie, Inc., North Chicago, Illinois, USA.
- AbbVie Bioresearch Center, Worcester, Massachusetts, USA.
ORCID-Profile: Xiaoguang Li
Förderung
- AbbVie Inc.
- AbbVie
Zitieren
APA
Li, X., Rahimov, F., Wang, R., Gao, L., Ma, R., Han, T., Bi, Y., Cruz, F., Wang, J., Grosskurth, S., Asque, E., Paez-Cortez, J., Levesque, M. C., Crosbie, N. E., Radstake, T., Biswas, A., & Katlinski, K. (2026). A Novel PTPN2 Isoform Differentially Regulates Immune Response. European Journal of Immunology, 56(5). https://doi.org/10.1002/eji.70207
Vancouver
Li X, Rahimov F, Wang R, Gao L, Ma R, Han T, et al. A Novel PTPN2 Isoform Differentially Regulates Immune Response. European Journal of Immunology. 2026;56(5). doi:10.1002/eji.70207
BibTeX
@article{Li2026,
author = {Li, Xiaoguang and Rahimov, Fedik and Wang, Rui and Gao, Lei and Ma, Renze and Han, Tiankai and Bi, Yingtao and Cruz, Freidrich and Wang, Jing and Grosskurth, Shaun and Asque, Elizabeth and Paez-Cortez, Jesus and Levesque, Marc C and Crosbie, Nancy E and Radstake, Timothy and Biswas, Amlan and Katlinski, Kanstantsin},
title = {A Novel PTPN2 Isoform Differentially Regulates Immune Response},
journal = {European Journal of Immunology},
year = {2026},
volume = {56},
number = {5},
doi = {10.1002/eji.70207}
}
EUVIMED